A detailed history of Alliancebernstein L.P. transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Alliancebernstein L.P. holds 454,788 shares of ASND stock, worth $62 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
454,788
Previous 475,001 4.26%
Holding current value
$62 Million
Previous $64.8 Million 4.84%
% of portfolio
0.02%
Previous 0.02%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$113.0 - $153.43 $2.28 Million - $3.1 Million
-20,213 Reduced 4.26%
454,788 $67.9 Million
Q2 2024

Aug 14, 2024

BUY
$121.07 - $153.67 $151,095 - $191,780
1,248 Added 0.26%
475,001 $64.8 Million
Q1 2024

May 14, 2024

SELL
$123.45 - $159.4 $14.2 Million - $18.4 Million
-115,183 Reduced 19.56%
473,753 $71.6 Million
Q4 2023

Feb 14, 2024

SELL
$86.1 - $127.36 $1.2 Million - $1.78 Million
-13,938 Reduced 2.31%
588,936 $74.2 Million
Q3 2023

Nov 14, 2023

BUY
$86.5 - $103.97 $2.12 Million - $2.55 Million
24,487 Added 4.23%
602,874 $56.5 Million
Q2 2023

Aug 15, 2023

BUY
$69.96 - $97.84 $4.43 Million - $6.2 Million
63,329 Added 12.3%
578,387 $51.6 Million
Q1 2023

May 15, 2023

BUY
$104.9 - $126.78 $2.63 Million - $3.18 Million
25,112 Added 5.13%
515,058 $55.2 Million
Q4 2022

Feb 14, 2023

SELL
$99.42 - $131.97 $14.9 Million - $19.8 Million
-149,930 Reduced 23.43%
489,946 $59.8 Million
Q3 2022

Nov 15, 2022

SELL
$84.03 - $110.23 $3.69 Million - $4.84 Million
-43,920 Reduced 6.42%
639,876 $66.1 Million
Q2 2022

Aug 15, 2022

SELL
$78.08 - $117.61 $1.96 Million - $2.95 Million
-25,085 Reduced 3.54%
683,796 $63.6 Million
Q1 2022

May 13, 2022

SELL
$102.18 - $135.75 $129,870 - $172,538
-1,271 Reduced 0.18%
708,881 $83.2 Million
Q4 2021

Feb 14, 2022

BUY
$127.1 - $169.66 $19.3 Million - $25.8 Million
152,221 Added 27.28%
710,152 $95.5 Million
Q3 2021

Nov 10, 2021

SELL
$112.67 - $176.92 $2.76 Million - $4.33 Million
-24,467 Reduced 4.2%
557,931 $88.9 Million
Q2 2021

Jul 30, 2021

BUY
$121.62 - $145.29 $12.5 Million - $15 Million
103,056 Added 21.5%
582,398 $76.6 Million
Q1 2021

May 06, 2021

BUY
$124.92 - $173.33 $2.1 Million - $2.91 Million
16,809 Added 3.63%
479,342 $61.8 Million
Q4 2020

Feb 08, 2021

SELL
$151.2 - $182.76 $902,361 - $1.09 Million
-5,968 Reduced 1.27%
462,533 $77.1 Million
Q3 2020

Nov 12, 2020

BUY
$134.29 - $154.32 $2.88 Million - $3.31 Million
21,467 Added 4.8%
468,501 $72.3 Million
Q2 2020

Aug 13, 2020

SELL
$110.87 - $156.01 $6.23 Million - $8.77 Million
-56,223 Reduced 11.17%
447,034 $66.1 Million
Q1 2020

May 14, 2020

SELL
$97.01 - $145.11 $3.28 Million - $4.91 Million
-33,829 Reduced 6.3%
503,257 $56.7 Million
Q4 2019

Feb 18, 2020

BUY
$91.45 - $139.12 $177,413 - $269,892
1,940 Added 0.36%
537,086 $74.7 Million
Q3 2019

Nov 14, 2019

BUY
$95.8 - $118.9 $3.04 Million - $3.77 Million
31,741 Added 6.31%
535,146 $51.5 Million
Q2 2019

Aug 14, 2019

SELL
$107.11 - $132.09 $11.5 Million - $14.2 Million
-107,449 Reduced 17.59%
503,405 $58 Million
Q1 2019

May 14, 2019

SELL
$62.15 - $129.99 $4.71 Million - $9.85 Million
-75,790 Reduced 11.04%
610,854 $71.9 Million
Q4 2018

Feb 13, 2019

SELL
$55.16 - $69.67 $1.53 Million - $1.93 Million
-27,722 Reduced 3.88%
686,644 $43 Million
Q3 2018

Nov 08, 2018

BUY
$63.77 - $76.28 $1.21 Million - $1.45 Million
19,039 Added 2.74%
714,366 $50.6 Million
Q2 2018

Aug 13, 2018

SELL
$58.55 - $73.92 $2.23 Million - $2.81 Million
-38,056 Reduced 5.19%
695,327 $46.3 Million
Q1 2018

May 14, 2018

BUY
$38.98 - $68.04 $26.4 Million - $46.1 Million
677,843 Added 1220.46%
733,383 $48 Million
Q4 2017

Feb 13, 2018

BUY
$31.98 - $40.38 $816,769 - $1.03 Million
25,540 Added 85.13%
55,540 $2.23 Million
Q3 2017

Nov 13, 2017

BUY
$26.89 - $37.1 $806,700 - $1.11 Million
30,000
30,000 $1.09 Million

Others Institutions Holding ASND

About Ascendis Pharma A/S


  • Ticker ASND
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,810,200
  • Market Cap $7.61B
  • Description
  • Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...
More about ASND
Track This Portfolio

Track Alliancebernstein L.P. Portfolio

Follow Alliancebernstein L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

News

Stay updated on Alliancebernstein L.P. with notifications on news.